ASML Holding NV vs Bristol-Myers Squibb Company: Strategic Comparison

This in-depth comparison examines ASML Holding NV and Bristol-Myers Squibb Company across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching ASML Holding NV on its own, evaluating Bristol-Myers Squibb Company, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between ASML Holding NV and Bristol-Myers Squibb Company is widest.

On the headline numbers, ASML Holding NV reports annual revenue of ~$36.9B against $48.2B for Bristol-Myers Squibb Company, while their respective market capitalizations stand at $696.4B and $127.5B. ASML Holding NV is headquartered in Netherlands and Bristol-Myers Squibb Company in United States, and those different home markets shape how each company competes.

ASML Holding NV: ASML is the most consequential technology company most consumers have never heard of. Based in Veldhoven in the Netherlands, it is the only supplier of extreme ultraviolet lithography machines, room-sized systems that use 13.5 nanometer light, plasma generated from molten tin, and mirrors polished to near-atomic smoothness to print circuit patterns onto silicon wafers. Without them, chipmakers such as TSMC, Samsung and Intel cannot manufacture the leading-edge logic and memory used in phones, data centers and AI accelerators. ASML sold 535 systems in 2025 and reported total net sales of ~$37 billion (32.7 billion euros).

Bristol-Myers Squibb Company: Bristol Myers Squibb (BMS) is a U.S. biopharmaceutical company headquartered in Princeton, New Jersey, and listed on the New York Stock Exchange as BMY. It develops and sells prescription medicines for cancer, blood disorders, immune diseases, heart disease and schizophrenia. Its best-known products are Eliquis, the anticoagulant it sells with Pfizer, and Opdivo, a PD-1 checkpoint inhibitor. With $48.2 billion of 2025 revenue and a market value of about $127 billion at the end of September 2026, it is one of the largest U.S. drugmakers by sales.

ASML Holding NV and Bristol-Myers Squibb Company pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between ASML Holding NV and Bristol-Myers Squibb Company.

ASML Holding NV business model: ASML designs and assembles lithography systems, sells them to a small number of chipmakers, and then earns recurring revenue maintaining and upgrading the installed base. In 2025, net system sales were ~$27.7 billion (24.5 billion euros), or 74.9 percent of total net sales, and net service and field option sales were ~$9.27 billion (8.2 billion euros), or 25.1 percent. Customer concentration is extreme: four customers each accounted for more than 10 percent of 2025 net sales and together for 61.2 percent, while the single largest customer accounted for ~$8.81 billion (7.8 billion euros), or 23.9 percent. ASML works as a systems integrator rather than a vertically integrated manufacturer. It buys all lenses, mirrors, illuminators and collectors exclusively from Carl Zeiss SMT, in which it holds a 24.9 percent stake, and draws on a base of about 5,100 suppliers. Because systems take many months to build, customers pay substantial down payments before delivery.

Bristol-Myers Squibb Company business model: BMS discovers, licenses or buys drug candidates, takes them through clinical trials, and sells approved medicines under patent protection to wholesalers, specialty pharmacies and hospitals. Net product sales were $46.8 billion of the $48.2 billion total in 2025; alliance, royalty and other revenues made up the remaining $1.4 billion, including royalties from Merck on Winrevair. Eliquis is developed and sold with Pfizer, which shares its costs and profits. About 69 percent of 2025 revenue came from the United States, so U.S. pricing policy matters more to BMS than to most European rivals. Because every patent runs out, the model depends on replacing revenue: BMS paid $74 billion for Celgene in 2019, $13.1 billion for MyoKardia in 2020 and about $23 billion for Karuna, Mirati and RayzeBio in early 2024.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of ASML Holding NV stack up against those of Bristol-Myers Squibb Company.

ASML Holding NV competitive advantage: ASML's competitive advantage is the difficulty of building an EUV machine at all. The system fires a high-power laser at molten tin droplets roughly 50,000 times a second to create a plasma that emits 13.5 nanometer light, which cannot pass through glass or air and so must be steered by mirrors polished to near-atomic smoothness inside a vacuum. Those optics come only from Carl Zeiss SMT, under an exclusive arrangement, and ASML spent roughly two decades between the start of EUV research and the first production shipments in 2017 before the technology worked at commercial throughput. The company spent ~$5.31 billion (4.7 billion euros) on R&D in 2025 alone, 14.4 percent of sales, and coordinates about 5,100 suppliers to build the systems.

Bristol-Myers Squibb Company competitive advantage: BMS's advantage is its expertise in oncology and its large commercial and regulatory organization. Developing a cancer immunotherapy is complex, and winning approval from regulators and getting doctors to prescribe it requires an established global sales and regulatory team. Smaller biotech companies often lack that infrastructure, so they partner with or sell to a company like BMS to bring their discoveries to market.

Future prospects matter as much as current results. The growth strategies below explain how ASML Holding NV and Bristol-Myers Squibb Company each plan to expand from here.

ASML Holding NV growth strategy: Growth depends on how fast chipmakers add advanced capacity and on how quickly ASML can build systems. In EUV, the workhorse is the TWINSCAN NXE:3800E, whose higher productivity drove 2025 EUV sales and a large volume of field upgrades on installed systems; ASML recognized 44 NXE systems for ~$11.8 billion (10.4 billion euros) in 2025. The next step is the High-NA EXE platform, which raises numerical aperture from 0.33 to 0.55 and prints 8 nanometer features in a single exposure. ASML shipped its first full-specification EXE:5200B in April 2025 at 175 wafers per hour, 60 percent more productive than the EXE:5000, recognized four EXE systems for ~$1.36 billion (1.2 billion euros) in 2025, and expects the platform to support high-volume manufacturing from 2027. Beyond lithography, ASML is pushing multibeam e-beam inspection toward high-volume manufacturing, shipped its first advanced packaging system the TWINSCAN XT:260 in 2025 to address 3D integration, and invested ~$1.47 billion (1.3 billion euros) in Mistral AI for about 11 percent on a fully diluted basis to apply AI models across its products and operations. Service and field option sales, which grew 26.2 percent to ~$9.27 billion (8.2 billion euros) in 2025, expand automatically with the installed base.

Bristol-Myers Squibb Company growth strategy: BMS is pursuing growth on three fronts. First, scaling the Growth Portfolio (Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag, Cobenfy and others), which rose 17 percent to $26.4 billion in 2025 and 15 percent to $7.56 billion in the second quarter of 2026. Second, buying and licensing late-stage science: Mirati ($4.8 billion plus a contingent value right of up to $1 billion), RayzeBio ($4.1 billion) and Karuna ($14 billion) closed in early 2024; a June 2025 deal with BioNTech for the bispecific BNT327 carried $1.5 billion upfront and up to $11.1 billion in total; and Orbital Therapeutics was bought for $1.5 billion in October 2025 for in vivo CAR-T in autoimmune disease. Third, cost cuts: a $1.5 billion savings program announced in 2024 was extended in 2025 with a further $2 billion targeted by the end of 2027.

A closer look at the financial trajectory of ASML Holding NV and Bristol-Myers Squibb Company rounds out the comparison.

ASML Holding NV: ASML's financial profile reflects a sole-source position in a concentrated market. In 2025 total net sales rose 15.6 percent to ~$37 billion (32.7 billion euros), gross profit was ~$19.5 billion (17.3 billion euros) for a gross margin of 52.8 percent, income from operations was ~$12.8 billion (11.3 billion euros), and net income was ~$10.8 billion (9.6 billion euros), a net margin of 29.4 percent, on basic earnings per share of 24.73 euros. R&D spending was ~$5.31 billion (4.7 billion euros), or 14.4 percent of sales, and selling, general and administrative costs were ~$1.47 billion (1.3 billion euros). Operating cash flow was ~$14.4 billion (12.7 billion euros) and free cash flow ~$12.4 billion (11.0 billion euros), helped by customer down payments received before systems are delivered. ASML returned ~$9.61 billion (8.5 billion euros) to shareholders in 2025, including ~$6.67 billion (5.9 billion euros) of share buybacks, and proposed an annualized dividend of 7.50 euros per share against 6.40 euros for 2024. It held ~$15 billion (13.3 billion euros) of cash and short-term investments at year end. The main financial exposures are the concentration of sales in a few customers and the export control regime covering China, which was 29.1 percent of 2025 sales.

Bristol-Myers Squibb Company: Revenue grew from $19.4 billion in 2016 to $42.5 billion in 2020 as Celgene's sales were added, and has stayed between $45.0 billion and $48.3 billion since 2021. Net earnings are far less stable because BMS expenses acquired in-process R&D: the $11.4 billion MyoKardia charge produced a $9.0 billion net loss in 2020, and the Karuna charge produced an $8.9 billion loss in 2024. Cash generation is steadier, with free cash flow of about $12.8 billion in 2025. That cash funds a dividend raised for a 17th straight year in February 2026, to $0.63 a quarter, and debt reduction, from $51.2 billion at the end of 2024 to $47.2 billion a year later. On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion, from $46.0 to $47.5 billion, after second-quarter revenue rose 6 percent to $12.97 billion.